BLA 761116 · Stemline Therapeutics INC
Elzonris
Tagraxofusp-Erzs · Injection · CD123 Interaction; Cytotoxin
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Dec 21, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
23
0 Phase 3, 10 recruiting
FAERS reports
538
459 serious, 161 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CAPILLARY LEAK SYNDROME Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended [see Warnings and Precautions ( 5.1 )] . WARNING: CAPILLARY LEAK SYNDROME See full prescribing information for complete boxed warning. Capillary Leak Syndrome (CLS), which may be life-threatening or fatal if not properly managed, can occur in patients receiving ELZONRIS. ( 5.1 )
What it is approved for
From the label in effect Dec 9, 2024.
ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older ( 1 )
Mechanism: Tagraxofusp-erzs is a CD123-directed cytotoxin composed of recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT) fusion protein that inhibits protein synthesis and causes cell death in CD123-expressing cells. 12.2 Pharmacodynamics The exposure-response relationships and the time course of pharmacodynamic response for ELZONRIS have not been fully characterized. 12.6 Immunogenicity The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody)...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 27, 2022 Supplement 5 · Efficacy OrphanLetterLabel
- Dec 21, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelReview
1 products under this application
- ELZONRIS · TAGRAXOFUSP-ERZS 1000MCG · SOLUTION, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tagraxofusp" as an intervention, any sponsor and status, largest first.
AbbVieAbbVie (ABBV)
NCT03386513 · 179 participants · Start Jan 2, 2018 · Primary completion Oct 2, 2024
Drug: IMGN632 · For: Blastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 18 sites in all
- Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid LeukemiaCompleted
Stemline Therapeutics, Inc.Industry
NCT02113982 · 138 participants · Start Sep 2014 · Primary completion Feb 1, 2020
Drug: Tagraxofusp · For: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Acute Myeloid Leukemia (AML)
Sites: Duarte, California; Tampa, Florida; Boston, Massachusetts · 9 sites in all
- A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyActive, not recruiting
Stemline Therapeutics, Inc.Industry
NCT06456463 · 85 participants · Start Jan 14, 2025 · Primary completion Feb 9, 2028
Drug: Tagraxofusp; Venetoclax and 1 more · For: Acute Myeloid Leukemia
Sites: Los Angeles, California; Stanford, California; Miami, Florida · 32 sites in all
Stemline Therapeutics, Inc.Industry
NCT02268253 · 82 participants · Start Feb 10, 2016 · Primary completion Mar 27, 2023
Drug: Tagraxofusp Injection · For: Myelofibrosis; Chronic Myelomonocytic Leukemia
Sites: Clovis, California; Duarte, California; Los Angeles, California · 24 sites in all
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT03113643 · 72 participants (planned) · Start Jun 26, 2017 · Primary completion Sep 15, 2021
Drug: Azacitidine; SL-401 and 1 more · For: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Blastic Plasmacytoid Dendritic Cell Neoplasm
Sites: Duarte, California; Boston, Massachusetts; Houston, Texas
- Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic SyndromesActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT05038592 · 64 participants (planned) · Start Mar 4, 2022 · Primary completion Jan 29, 2027
Drug: Decitabine; Tagraxofusp-erzs · For: Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2 and 1 more
Sites: Houston, Texas
Therapeutic Advances in Childhood Leukemia ConsortiumAcademic, hospital or other
NCT05476770 · 54 participants (planned) · Start Nov 11, 2022 · Primary completion Nov 11, 2025
Drug: Tagraxofusp; Fludarabine and 7 more · For: Hematologic Malignancy; AML; ALL and 8 more
Sites: Los Angeles, California; Orange, California; San Francisco, California · 31 sites in all
Joshua ZeidnerAcademic, hospital or other
NCT05442216 · 53 participants (planned) · Start May 1, 2024 · Primary completion Jul 21, 2030
Drug: Tagraxofusp; Azacitidine and 1 more · For: Acute Myeloid Leukemia
Sites: Miami, Florida; Orlando, Florida; Buffalo, New York · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- capillary leak syndrome130
- pyrexia47
- off label use43
- death41
- disease progression38
- thrombocytopenia35
- blood albumin decreased29
- drug ineffective28
- weight increased28
- tumour lysis syndrome27
- hypoalbuminaemia25
- acute kidney injury24
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 58 |
| 2020 | 60 |
| 2021 | 75 |
| 2022 | 72 |
| 2023 | 87 |
| 2024 | 69 |
| 2025 | 63 |
| 2026 | 54 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Elzonris (Tagraxofusp-Erzs) · HCPCS J9269
2024 spending
$15.0M
Beneficiaries
11
262 claims
Per beneficiary
$1,366,700
2024 ASP limit $329.44 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,778,976 |
| 2021 | $7,755,186 |
| 2022 | $9,179,726 |
| 2023 | $7,534,546 |
| 2024 | $15,033,699 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Pemmaraju N, Lane AA, Sweet KL, et al. · N Engl J Med 2019 · Clinical Trial, Multicenter Study
- Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
Lane AA, Garcia JS, Raulston EG, et al. · Blood Adv 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.
Pemmaraju N, Konopleva M · Blood Adv 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm.
Konopleva M, Pemmaraju N, Sweet KL, et al. · Cancer 2026 · Clinical Trial, Phase II
- Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study.
Patnaik MM, Ali H, Wang ES, et al. · Blood Neoplasia 2025 · Clinical Trial
- Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm.
Lane AA, Luskin MR, Keating J, et al. · Blood 2026 · Clinical Trial, Phase II
Sponsor: Stemline Therapeutics INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.